S913
Clinical - Mixed sites & palliation
ESTRO 2026
Follow-up questionnaires were automatically sent via email every 3 months in the first year and annually thereafter. Data were uploaded on the Value Based Medicine (VBM) IEO platform. Two professionals (a research coordinator and a research nurse) monitored the process through a dedicated dashboard. Data collected between November 2023 and August 2025 were analyzed, focusing on prostate, breast, and head and neck cancers.
Poster Discussion 4219
Optimization of Patient-Reported Quality of Life Data Collection in Proton Therapy: The Power Registry Experience Salvatore Biagio Valia 1 , Cristiana Iuliana Fodor 1 , Roberta Ugolini 2 , Maria Giulia Vincini 3 , Daniela Alterio 3 , Ilaria Repetti 3 , Chiara Lorubbio 3 , Giammaria Bufi 3 , Giulia Peruzzotti 1 , Roberto Orecchia 1 , Barbara Alicja Jereczek-Fossa 3,4 1 Scientific Direction, European Institute of Oncology, Milan, Italy. 2 Health Directorate, European Institute of Oncology, Milan, Italy. 3 Department of Radiation Oncology, European Institute of Oncology, Milan, Italy. 4 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy Purpose/Objective: Patients’ Quality of Life (QoL) is a key parameter in clinical oncology, recognizing that survival alone is not the only relevant outcome. The Proton Registry (Power Registry, NCT05860361) is a prospective, harmonized tool for collecting high-quality patient-reported data in proton therapy (PT). This abstract reports the preliminary experience with QoL self-reported questionnaires among patients treated at the Proton Center of the European Institute of Oncology (IEO), Milan, Italy. Material/Methods: All PT patients were invited to complete validated EORTC patient-reported outcome questionnaires, selected according to cancer site. Twenty-five questionnaires were implemented, with overlap among sites: 17 for head and neck, 8 for breast, 9 for prostate, 10 for gynecology, 8 each for anal canal, pancreas, lung, rectum, central nervous system, and esophagus, and 7 each for skin, kidney, and sarcoma, and 9 for bladder (Table 1). Patients completed questionnaires at baseline and end of treatment on- site via dedicated tablets to enhance adherence.
Results: A total of 321 patients underwent PT in the period analyzed. Median age was 64.3 years (range 20.7– 88.6). Overall, 4,250 questionnaires were completed. Completion rates were 90.7% at baseline and 85.9% at end of treatment, then 58%, 44.9%, and 34.5% at 3, 6, and 12 months, respectively. Figure 1 shows completion trends for prostate, breast, and head and neck cancers. Across sites, baseline completion ranged 55–95%, declining to 20–50% at 12 months.
Conclusion: Our preliminary findings demonstrate that the automatized workflow implemented for the Power Registry is an effective and efficient strategy in collecting high-quality patients’ QoL data. However, challenges persist after the end of the treatment
Made with FlippingBook - Share PDF online